GENE Genetic Technologies Limited: Rasio rega marang prakiraan pendapatan
Genetic Technologies aims to integrate predictive PRS tests into the standard of care for cancer and cardiac pathology prevention. Capitalization growth is driven by the expansion of AI diagnostics in the US and Australia, supported by high margins on consumables. However, the lack of stable cash flow leaves the company dependent on the pace of technology adoption. The forward P/S trend clearly illustrates market expectations, with the value fixed at 0.70.
Rincian analitis perusahaan Genetic Technologies
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Total Utang marang Modal Genetic Technologies|GENE - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Genetic Technologies Limited|GENE - Gunggung utang perusahaan|Utang marang nilai buku Genetic Technologies Limited|GENE - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Genetic Technologies|Rasio cepet gtglabs.com
- rincian asil keuangan lan kelipatan valuasi:
GENE - Penghasilan resik perusahaan|Proyeksi bathi mangsa ngarep Genetic Technologies|GENE - Koefisien rega marang bathi|Pangali Forward P/E Genetic Technologies Limited|GENE - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Genetic Technologies Limited|GENE - Bathi operasional sadurunge amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Genetic Technologies|GENE - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan gtglabs.com|GENE - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Genetic Technologies
- rincian pendapatan lan dodolan:
Analisis kabeh metrik perusahaan:GTG Labs (GENE)
The forward P/S ratio determines the market value of an asset relative to projected sales volume, making it possible to identify hidden business degradation masked by a low price. Analyzing the forward price-to-sales ratio helps assess the scaling efficiency of Genetic Technologies (GENE) as a healthcare system partner implementing genetic testing for oncology risk diagnostics to avoid a value trap during capital freezes.
Pesaing wigati
Multiplikator Forward P/S A (Agilent)|Quest Diagnostics Inc. (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN - Rasio rega marang prakiraan pendapatan|EXAS (Exact Sciences Inc.) - Kapitalisasi marang prakiraan pendapatan|RVTY: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep bio-rad.com (BIO)|Multiplikator forward rega marang pendapatan NNNN|SHC (Sotera Health Corp) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S QDEL|Rasio kapitalisasi marang dodolan sing dikarepake OPKO Health Corp.|Multiplikator Forward P/S CDNA (CareDx, Inc)|MRVI - Multiplikator forward rega marang pendapatan|FLGT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan LAB (Standard BioTools Inc)|CTKB (Cytek Bio) - Multiplikator forward rega marang pendapatan|OSUR: Rasio rega marang pendapatan sing dikarepake|XGN (Exagen Inc) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep mdxhealth.com MDXH|Multiplikator Forward P/S LUCD|Multiplikator forward rega marang pendapatan prenetics.com PRE|Multiplikator Forward P/S IMDX (Insight Molecular Diagnostics Inc)|Rega forward marang dodolan TRIB|PRPH - Rasio rega marang prakiraan pendapatan|AIMD (ainos.com) - Kapitalisasi marang prakiraan pendapatan|Co-Diagnostics (CODX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Heart Test Laboratories, Inc. (HSCS)|Rasio rega marang prakiraan pendapatan Biomerica, Inc|Rasio rega marang prakiraan pendapatan CDIO|Rasio rega marang prakiraan pendapatan Onconetix, Inc. (ONCO)|VRAX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BJDX (Bluejay Diagnostics, Inc.)|Prakiraan rega marang pendapatan Aspira Women's Health, Inc.|Accelerate Diagnostics, Inc - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake CENTOGENE CNTG|ENZ: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fresh2 Group (FRES)|Rasio rega marang prakiraan pendapatan 23andMe|Psychemedics Corp. (PMD) - Rasio kapitalisasi marang dodolan sing dikarepake
